• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Ypsomed to expand drug delivery device manufacturing, add 200 jobs

June 29, 2023 By Sean Whooley

Ypsomed Logo 770x500Ypsomed announced today that, at its annual general meeting, its shareholders approved all proposals, including facility expansions.

Burgdorf, Switzerland-based Ypsomed develops drug delivery devices, including insulin pumps for those with diabetes. Its YpsoPump represents a leading offering as an automated insulin delivery system compatible with certain software and glucose monitors.

Board member Simon Michel confirmed the company’s commitment to Switzerland as a manufacturing location at the annual meeting. Ypsomed expects to create 200 new jobs in Burgdorf and Solothurn in the current financial year, on top of expansions elsewhere.

“In addition to expanding production in Schwerin [Germany] and setting up our own plant in China, we will continue to strengthen and expand our facilities in Switzerland,” said Michel.

Additionally, at the meeting, present members of the board approved the re-election of Gilbert Achermann. They also approved amendments to the Articles of Association and a long-term incentive plan.

“I would like to thank the shareholders for their trust,” Achermann said. “Ypsomed has the privilege of providing people with chronic conditions with vital therapies. I am delighted to be able to lead the company further down this path.”

More positives for Ypsomed

The bolstering of manufacturing follows about a year of positive developments across the board at Ypsomed. Here are some of the highlights:

  • In April 2022, the company partnered with Abbott and Camdiab on automated insulin delivery.
    • The three companies launched the system in November 2022.
    • The artificial pancreas received UK authorization in April of this year.
  • In October, the company unveiled a new autoinjector
  • This past January, Ypsomed completed the sale of mail-order retailer for diabetes care DiaExpert. This sale allows the company to focus on the manufacture and sale of its own medical technologies.
  • Just this month, Ypsomed and S3 Connected Health partnered on digital offerings.

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Technology Tagged With: Ypsomed

IN CASE YOU MISSED IT

  • Medtronic to invest $50M in India Diabetes center
  • Flat Medical partners with Mercury Medical on smart syringe distribution
  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS